Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813614 | 1.00 | MAPT (1.00) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12813753 | 0.80 | MEN1 (0.79) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12813751 | 0.80 | MEN1 (0.79) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| Piriqualone SCHEMBL2109756 | 0.78 | MEN1 (1.00) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11332327 | 0.78 | ALDH1A1 (0.69) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1961703 | 0.75 | MEN1 (0.74) | MAPTTP53MEN1KMT2ALMNA | |
| SCHEMBL15356692 | 0.75 | MEN1 (0.74) | MAPTTP53MEN1KMT2ALMNA | |
| SCHEMBL1961700 | 0.75 | MEN1 (0.74) | MAPTTP53MEN1KMT2ALMNA | |
| SCHEMBL19225062 | 0.75 | MAPT (0.63) | MAPTTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12566992 | 0.75 | MAPT (0.63) | MAPTTP53SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | TRANA DISCOVERY, INC. (US) | 2019-06-11 | — | — | US | claimed |
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2014-06-12 | — | — | US | claimed |
| EP-2691542-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | Trana Discovery, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| WO-2012135416-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | TRANA DISCOVERY, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | TRANA DISCOVERY, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2691542-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | Trana Discovery, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012135416-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135416-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | NSUN3, RNGTT, TRMT1 | MAPT 2009/4885TP53 1855/4885SMN1; SMN2 2843/4885 |
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | NSUN3, RNGTT, TRMT1 | MAPT 2009/4885TP53 1855/4885SMN1; SMN2 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.